NASDAQ:EGRX

Eagle Pharmaceuticals Stock Predictions

Healthcare > Drug Manufacturers - Specialty & Generic

Buy EGRX

*Your capital is at risk

$0.670

+0 (+0%)

At Close: Jul 10, 2026

Currently predicting for Tue, 14 Jul 2026

EGRX Live board

Community Bull/Bear

Target Next close

Join the EGRX prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

EGRX Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For EGRX

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

EGRX Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT EAGLE PHARMACEUTICALS

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	11.34%	Jun 29
NMRK $15.02	1.20%	Jun 24
NESR $25.07	14.16%	Jun 23
CAG $13.43	2.98%	Jun 23
GIB $66.69	0.555%	Jun 12

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by